38.14
price up icon1.86%   0.71
 
loading
전일 마감가:
$37.43
열려 있는:
$37.69
하루 거래량:
1.31M
Relative Volume:
0.52
시가총액:
$9.81B
수익:
$2.08B
순이익/손실:
$466.92M
주가수익비율:
24.45
EPS:
1.56
순현금흐름:
$404.94M
1주 성능:
+7.12%
1개월 성능:
+3.88%
6개월 성능:
+33.77%
1년 성능:
+60.86%
1일 변동 폭
Value
$37.59
$38.57
1주일 범위
Value
$35.80
$38.57
52주 변동 폭
Value
$20.14
$40.02

Exelixis Inc Stock (EXEL) Company Profile

Name
명칭
Exelixis Inc
Name
전화
(650) 837-7000
Name
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Name
직원
1,147
Name
트위터
@exelixisinc
Name
다음 수익 날짜
2025-02-11
Name
최신 SEC 제출 서류
Name
EXEL's Discussions on Twitter

EXEL을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
EXEL
Exelixis Inc
38.16 9.81B 2.08B 466.92M 404.94M 1.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.12 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
601.52 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
615.94 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.10 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
250.42 24.70B 3.81B -644.79M -669.77M -6.24

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-24 다운그레이드 Wells Fargo Overweight → Equal Weight
2025-01-27 업그레이드 Morgan Stanley Equal-Weight → Overweight
2025-01-24 다운그레이드 Oppenheimer Outperform → Perform
2024-12-20 다운그레이드 BMO Capital Markets Outperform → Market Perform
2024-12-17 다운그레이드 BofA Securities Buy → Neutral
2024-10-16 재확인 RBC Capital Mkts Outperform
2024-09-19 개시 UBS Neutral
2024-04-11 다운그레이드 Barclays Overweight → Equal Weight
2023-12-19 개시 BTIG Research Buy
2023-12-15 개시 Citigroup Buy
2023-09-26 개시 H.C. Wainwright Buy
2023-08-22 재확인 Oppenheimer Outperform
2023-08-08 개시 SVB Securities Market Perform
2023-07-11 재개 Morgan Stanley Equal-Weight
2023-05-10 재개 Piper Sandler Overweight
2023-03-09 개시 Wells Fargo Overweight
2023-01-26 개시 Credit Suisse Outperform
2022-10-18 개시 JMP Securities Mkt Outperform
2022-06-24 개시 BMO Capital Markets Outperform
2021-11-19 개시 Piper Sandler Overweight
2021-11-03 재개 Jefferies Buy
2021-10-07 개시 Jefferies Buy
2021-08-06 재확인 H.C. Wainwright Buy
2021-06-15 개시 H.C. Wainwright Buy
2021-05-18 재개 Goldman Sell
2021-03-31 개시 Credit Suisse Outperform
2021-03-12 개시 Wolfe Research Outperform
2020-03-04 개시 Barclays Overweight
2020-01-13 개시 SunTrust Buy
2019-11-13 개시 BofA/Merrill Buy
2019-03-18 업그레이드 Morgan Stanley Underweight → Equal-Weight
2018-09-17 개시 Goldman Neutral
2018-09-10 개시 Morgan Stanley Underweight
2018-05-11 재확인 Needham Buy
2017-10-17 재확인 Needham Buy
2017-10-17 재확인 RBC Capital Mkts Outperform
2017-10-16 재확인 SunTrust Buy
2017-09-22 다운그레이드 Leerink Partners Outperform → Mkt Perform
2017-09-15 개시 RBC Capital Mkts Outperform
2017-09-12 재확인 Needham Buy
2017-07-14 개시 SunTrust Buy
2017-03-31 개시 Needham Buy
2017-03-16 개시 Oppenheimer Perform
2017-02-28 다운그레이드 Stifel Buy → Hold
2016-11-03 개시 Deutsche Bank Buy
2016-10-10 업그레이드 Piper Jaffray Neutral → Overweight
2016-09-15 재확인 Stifel Buy
모두보기

Exelixis Inc 주식(EXEL)의 최신 뉴스

pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? - The Globe and Mail

Apr 25, 2025
pulisher
Apr 24, 2025

Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance

Apr 24, 2025
pulisher
Apr 22, 2025

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance

Apr 22, 2025
pulisher
Apr 17, 2025

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts - Benzinga

Apr 17, 2025
pulisher
Apr 17, 2025

Citizens JMP reiterates Exelixis stock with $41 target By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 17, 2025

Citizens JMP reiterates Exelixis stock with $41 target - Investing.com

Apr 17, 2025
pulisher
Apr 17, 2025

Exelixis, Inc. (NASDAQ:EXEL) Position Boosted by Summit Investment Advisors Inc. - MarketBeat

Apr 17, 2025
pulisher
Apr 16, 2025

Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings - simplywall.st

Apr 16, 2025
pulisher
Apr 16, 2025

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Apr 16, 2025
pulisher
Apr 16, 2025

(EXEL) Investment Analysis - news.stocktradersdaily.com

Apr 16, 2025
pulisher
Apr 11, 2025

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Apr 11, 2025
pulisher
Apr 10, 2025

Prostate Cancer Pipeline Analysis and Clinical Trials - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca

Apr 10, 2025
pulisher
Apr 09, 2025

Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis - openPR.com

Apr 09, 2025
pulisher
Apr 09, 2025

Guggenheim maintains Exelixis stock with $42 target By Investing.com - Investing.com India

Apr 09, 2025
pulisher
Apr 09, 2025

Guggenheim maintains Exelixis stock with $42 target - Investing.com

Apr 09, 2025
pulisher
Apr 08, 2025

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance

Apr 08, 2025
pulisher
Apr 05, 2025

Exelixis (EXEL) Gets a Buy from RBC Capital - The Globe and Mail

Apr 05, 2025
pulisher
Apr 03, 2025

The Smartest Biotech Stocks to Buy With $50 - The Motley Fool

Apr 03, 2025
pulisher
Apr 03, 2025

FY2026 EPS Estimates for Exelixis Lifted by Leerink Partnrs - MarketBeat

Apr 03, 2025
pulisher
Apr 02, 2025

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now? - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Trexquant Investment LP Has $19.82 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Blair William & Co. IL Sells 300,760 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 02, 2025
pulisher
Apr 01, 2025

New Age Alpha Advisors LLC Makes New $2.10 Million Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Exelixis Launches Special Equity Award Program - TipRanks

Mar 31, 2025
pulisher
Mar 30, 2025

(EXEL) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 30, 2025
pulisher
Mar 29, 2025

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

What is Leerink Partnrs' Estimate for Exelixis Q1 Earnings? - MarketBeat

Mar 29, 2025
pulisher
Mar 28, 2025

Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Exelixis stock holds $40 target post FDA nod By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 27, 2025

FDA Expands Exelixis Cabometyx Label For Neuroendocrine Tumors - Barchart.com

Mar 27, 2025
pulisher
Mar 27, 2025

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL) - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Exelixis stock holds $40 target post FDA nod - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Stifel maintains Exelixis stock hold, $36 target post FDA nod By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 26, 2025

FDA approves new treatment for advanced neuroendocrine tumors By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis to present positive preclinical data across pipeline portfolio at AACR - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Leerink lifts Exelixis stock target to $33 post FDA approval By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - Yahoo

Mar 26, 2025
pulisher
Mar 26, 2025

Leerink lifts Exelixis stock target to $33 post FDA approval - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Stifel maintains Exelixis stock hold, $36 target post FDA nod - Investing.com India

Mar 26, 2025

Exelixis Inc (EXEL) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.65
price up icon 0.63%
$70.47
price up icon 1.28%
$32.49
price up icon 0.64%
$23.90
price up icon 1.85%
$108.35
price up icon 3.89%
biotechnology ONC
$247.87
price up icon 1.21%
자본화:     |  볼륨(24시간):